



Schweizerische Pädiatrische Onkologie Gruppe
Groupe d'Oncologie Pédiatrique Suisse
Gruppo d'Oncologia Pediatrica Svizzera
Swiss Paediatric Oncology Group

LCH-IV

The St. Anna Kinderkrebsforschung in Austria is responsible for the international implementation of the study as sponsor. The Swiss Paediatric Oncology Group (SPOG) is responsible for performing the study in Switzerland (sponsor representative).

Background

Langerhans cell histiocytosis, LCH for short, is a rare disorder of the immune system in which certain immune cells turn against the patient's own body. Various organs can be affected and damaged by LCH. This variable clinical picture requires different therapeutic approaches in order to cure affected children and adolescents.

Why does the trial need to be done?

Because of the complexity of the clinical picture of LCH and its complications, this trial will provide treatment adapted to the characteristics of the disease. Patients will be assigned to groups on the basis of the organs that are affected when the diagnosis is made and treated accordingly. The patients' response to the therapy will be reviewed continuously during the trial, as will the need to intensify the treatment. The efficacy of stem cell transplantation will be investigated in patients with a very severe form of the disease who have a particularly unfavourable prognosis because they do not respond to the conventional therapy. After the treatment has been completed, all patients will be examined for possible recurrence of the disease and long-term complications.

Contact details for the sponsor representative in Switzerland:

Fundraising
SPOG Coordinating Center
Effingerstrasse 33
3008 Bern
Phone: +41 31 389 91 89